IPO Bind Therapeutics Inc (BIND) is a clinical-stage nanomedicine platform company developing Accurins. Accurins are programmable therapeutics designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment